Global Patent Index - EP 2854798 A4

EP 2854798 A4 20160511 - COMPOSITIONS COMPRISING ISOSILYBIN B FOR AMELIORATION AND PREVENTION OF DRUG- INDUCED TOXICITY

Title (en)

COMPOSITIONS COMPRISING ISOSILYBIN B FOR AMELIORATION AND PREVENTION OF DRUG- INDUCED TOXICITY

Title (de)

ZUSAMMENSETZUNGEN MIT ISOSILYBIN B ZUR BEHANDLUNG UND VORBEUGUNG VON WIRKSTOFFINDUZIERTER TOXIZITÄT

Title (fr)

COMPOSITIONS COMPRENANT DE L'ISOSILYBINE B POUR L'AMÉLIORATION ET LA PRÉVENTION DE LA TOXICITÉ INDUITE PAR UN MÉDICAMENT

Publication

EP 2854798 A4 20160511 (EN)

Application

EP 13793975 A 20130523

Priority

  • US 201261651005 P 20120524
  • US 201261654971 P 20120604
  • IL 2013050446 W 20130523

Abstract (en)

[origin: WO2013175479A1] Compositions comprising isosilybin B and optionally additional protective agents selected from methylsulfonylmethane (MSM), phosphatidylcholine (PC), cysteine (Cys), seleno-cysteine (Se-Cys), ribose-cysteine (RibCys), N-acetylcysteine (NAC), N- acetylcysteine-amide (AD4), methionine (Met) and S-adenosylmethionine (SAM) for use in reducing and / or preventing drug- induced toxicity, such as acetaminophen-induced toxicity. Said compositions further comprising acetaminophen for use as safe formulations of acetaminophen with reduced risk of causing liver damage.

IPC 8 full level

A61K 31/357 (2006.01); A61K 31/353 (2006.01); A61K 45/06 (2006.01); A61P 1/16 (2006.01)

CPC (source: EP US)

A61K 31/10 (2013.01 - EP US); A61K 31/167 (2013.01 - EP US); A61K 31/197 (2013.01 - EP US); A61K 31/198 (2013.01 - EP US); A61K 31/357 (2013.01 - EP US); A61K 31/661 (2013.01 - EP US); A61K 31/685 (2013.01 - EP US); A61K 31/7056 (2013.01 - EP US); A61K 31/7076 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 1/16 (2017.12 - EP)

C-Set (source: EP US)

  1. A61K 31/167 + A61K 2300/00
  2. A61K 31/357 + A61K 2300/00
  3. A61K 31/10 + A61K 2300/00
  4. A61K 31/685 + A61K 2300/00
  5. A61K 31/198 + A61K 2300/00
  6. A61K 31/7056 + A61K 2300/00
  7. A61K 31/7076 + A61K 2300/00

Citation (search report)

  • [XI] US 2011124718 A1 20110526 - MCCAIN MARK D [US]
  • [X] US 2007021376 A1 20070125 - GIAMPAPA VINCENT C [US]
  • [X] US 6495170 B1 20021217 - SMIT HOBBE FRISO [NL], et al
  • [XI] WO 2005094862 A1 20051013 - LIFELINE NUTRACEUTICALS CORP [US], et al
  • [A] BABAK NAKHOSTIN-ROOHI ET AL: "Effect of chronic supplementation with methylsulfonylmethane on oxidative stress following acute exercise in untrained healthy men", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 63, no. 10, 1 August 2011 (2011-08-01), LONDON; GB, pages 1290 - 1294, XP055229223, ISSN: 0022-3573, DOI: 10.1111/j.2042-7158.2011.01314.x
  • [A] H JAESCHKE: "The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity", TOXICOLOGY LETTERS., vol. 144, no. 3, 15 October 2003 (2003-10-15), NL, pages 279 - 288, XP055229418, ISSN: 0378-4274, DOI: 10.1016/S0378-4274(03)00239-X
  • [A] J. L. WOODHEAD ET AL: "An Analysis of N-Acetylcysteine Treatment for Acetaminophen Overdose Using a Systems Model of Drug-Induced Liver Injury", PHARMACOLOGICAL REVIEWS, vol. 342, no. 2, 16 May 2012 (2012-05-16), US, pages 529 - 540, XP055261002, ISSN: 0031-6997, DOI: 10.1124/jpet.112.192930
  • See references of WO 2013175479A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2013175479 A1 20131128; EP 2854798 A1 20150408; EP 2854798 A4 20160511; US 2015080348 A1 20150319; US 9474763 B2 20161025

DOCDB simple family (application)

IL 2013050446 W 20130523; EP 13793975 A 20130523; US 201414551724 A 20141124